BioVisioN receives research grant within BioChancePLUS program
BioVisioN AG announced the receipt of approval of a research grant within the German BioChancePLUS program. The German Federal Ministry of education and Research (BMBF) will fund the Project on "Functional Peptidomics" that aims at the characterisation of proteases and protease inhibitors with 560,000 EUR. In the project BioVisioN will apply its patent-protected Peptidomics® technologies to analyse substrates and products of proteases in vivo. The inhibition of proteases is an important mode of action of therapies in fields like diabetes and thrombosis.
By investigating the action of several protease inhibitors in animal models, BioVisioN will discover biomarkers for drug efficacy and possible side effects that can be used in early and advanced stages of drug development thus allowing early selection of the optimal drug candidate and the proper selection of patients responding to the drug, speeding up drug development and contributing to cost reduction.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Illinois researchers use pyrosequencing to study canine intestinal bacteria
A previously unknown bacterial enzyme makes new type of biodegradable polymer
DuPont Pioneer Gains Exclusive License for Genome-Editing Technology from Vilnius University
Making it easier to differentiate mirror-image molecules - Researchers have shown that mirror-image substances – so-called enantiomers – can be better distinguished using helical X-ray light
Mobile_phone_radiation_and_health
Why some people with brain markers of Alzheimer’s have no dementia
Epigenomics AG Announces Restructuring of U.S. and European Operations
